YMAB
Y-mAbs Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Company Profile
CEO
Michael Rossi
IPO Date
2018-09-21
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Y-mAbs Therapeutics, Inc.
CEO
Michael Rossi
IPO Date
2018-09-21
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| $0.00 |
| 19 Sept 2025 | Hamill Laura | director | D-Return | Disposed | 27,000 | $48.67 |
| 19 Sept 2025 | Hamill Laura | director | D-Return | Disposed | 11,000 | $37.53 |
| 19 Sept 2025 | Hamill Laura | director | D-Return | Disposed | 16,000 | $16.64 |
| 19 Sept 2025 | Hamill Laura | director | D-Return | Disposed | 13,950 | $8.13 |
| 19 Sept 2025 | Hamill Laura | director | D-Return | Disposed | 14,545 | $12.01 |
| 19 Sept 2025 | Hamill Laura | director | D-Return | Disposed | 33,450 | $4.51 |
| 18 Sept 2025 | WG Biotech ApS | director, 10 percent owner: | U-Tender | Disposed | 4,559,233 | $8.60 |
| 18 Sept 2025 | Gentilcore Douglas J | SVP, Danyelza Bus. Unit Head | D-Return | Disposed | 142,600 | $6.16 |